{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:45:23Z","timestamp":1786974323934,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004740","name":"Fondazione del Monte di Bologna e Ravenna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008558","name":"East Carolina University Brody School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008501","name":"East Carolina University","doi-asserted-by":"publisher","award":["111104and #111110-668715-0000"],"award-info":[{"award-number":["111104and #111110-668715-0000"]}],"id":[{"id":"10.13039\/100008501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008501","name":"East Carolina University","doi-asserted-by":"publisher","award":["111110-668715-0000"],"award-info":[{"award-number":["111110-668715-0000"]}],"id":[{"id":"10.13039\/100008501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008501","name":"East Carolina University","doi-asserted-by":"publisher","award":["111104"],"award-info":[{"award-number":["111104"]}],"id":[{"id":"10.13039\/100008501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jbior.2021.100840","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T02:16:29Z","timestamp":1637633789000},"page":"100840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53"],"prefix":"10.1016","volume":"83","author":[{"given":"Stephen L.","family":"Abrams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaw M.","family":"Akula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Steelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde L.","family":"Follo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Libra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Falzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Montalto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchiorre","family":"Cervello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-3156","authenticated-orcid":false,"given":"James A.","family":"McCubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbior.2021.100840_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jbior.2018.06.002","article-title":"Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals","volume":"69","author":"Abrams","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2021.100840_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2020.100780","article-title":"Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53","volume":"79","author":"Abrams","year":"2021","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2021.100840_bib3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/cells10040816","article-title":"GSK-3\u03b2 can regulate the sensitivity of MIA-PaCa-2 pancreatic and MCF-7 breast cancer cells to chemotherapeutic drugs, targeted therapeutics and nutraceuticals","volume":"10","author":"Abrams","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jbior.2021.100840_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2019.04.003","article-title":"Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells","volume":"73","author":"Akula","year":"2019","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2021.100840_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbior.2018.02.002","article-title":"Metformin influences drug sensitivity in pancreatic cancer cells","volume":"68","author":"Candido","year":"2018","journal-title":"Adv. Biolog. Reg."},{"key":"10.1016\/j.jbior.2021.100840_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jbior.2019.03.002","article-title":"Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals","volume":"72","author":"Candido","year":"2019","journal-title":"Adv. Biol. Reg."},{"key":"10.1016\/j.jbior.2021.100840_bib7","doi-asserted-by":"crossref","first-page":"10194","DOI":"10.18632\/aging.103377","article-title":"Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf\/MEK\/ERK and PI3K\/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines","volume":"12","author":"Chappell","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jbior.2021.100840_bib8","doi-asserted-by":"crossref","first-page":"15 75","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe Francophone des my\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbior.2021.100840_bib9","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.18632\/oncotarget.2209","article-title":"Deregulation of the EGFR\/PI3K\/PTEN\/Akt\/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention","volume":"5","author":"Davis","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbior.2021.100840_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","article-title":"Phenotype and genotype of pancreatic cancer cell lines","volume":"39","author":"Deer","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.jbior.2021.100840_bib11","doi-asserted-by":"crossref","first-page":"8763","DOI":"10.1073\/pnas.86.22.8763","article-title":"Wild-type p53 can inhibit oncogene-mediated focus formation","volume":"86","author":"Eliyahu","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jbior.2021.100840_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ccell.2020.05.010","article-title":"Altered RNA splicing by mutant p53 activates oncogenic RAS signaling in pancreatic cancer","volume":"38","author":"Escobar-Hoyos","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2021.100840_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02788373","article-title":"Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells","volume":"19","author":"Frazier","year":"1996","journal-title":"Int. J. Pancreatol."},{"key":"10.1016\/j.jbior.2021.100840_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2016.09.008","article-title":"Molecular pathogenesis of pancreatic cancer","volume":"144","author":"Grant","year":"2016","journal-title":"Prog. Mol. Biol. Trans. Sci."},{"key":"10.1016\/j.jbior.2021.100840_bib15","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41467-019-12555-1","article-title":"Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia","volume":"10","author":"Hayashi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbior.2021.100840_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.471","article-title":"Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition","volume":"8","author":"Hou","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jbior.2021.100840_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.642603","article-title":"The gain-of-function p53 R248W mutant promotes migration by STAT3 deregulation in human pancreatic cancer cells","volume":"11","author":"Klemke","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbior.2021.100840_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cancers10010024","article-title":"Contemporary management of localized resectable pancreatic cancer","volume":"10","author":"Kommalapati","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.jbior.2021.100840_bib19","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2021.100840_bib20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.onc.1210707","article-title":"HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function","volume":"27","author":"Lau","year":"2008","journal-title":"Oncogene"},{"issue":"1\u20132","key":"10.1016\/j.jbior.2021.100840_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mrfmmm.2008.12.009","article-title":"Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage","volume":"662","author":"Liu","year":"2009","journal-title":"Mutat. Res."},{"key":"10.1016\/j.jbior.2021.100840_bib22","doi-asserted-by":"crossref","first-page":"12151","DOI":"10.2147\/OTT.S279002","article-title":"Berberine inhibits cell proliferation by interfering with wild-type and mutant P53 in human glioma cells","volume":"13","author":"Liu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.jbior.2021.100840_bib23","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2008.207","article-title":"Involvement of p53 and Raf\/MEK\/ERK pathways in hematopoietic drug resistance","volume":"22","author":"McCubrey","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2021.100840_bib24","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.18632\/aging.101250","article-title":"Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs","volume":"9","author":"McCubrey","year":"2017","journal-title":"Aging"},{"key":"10.1016\/j.jbior.2021.100840_bib25","first-page":"980","article-title":"Improved retroviral vectors for gene transfer and expression","volume":"7","author":"Miller","year":"1989","journal-title":"Biotechniques"},{"key":"10.1016\/j.jbior.2021.100840_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000510343","article-title":"Neoadjuvant chemotherapy in pancreatic cancer: an appraisal of the current high-level evidence","volume":"106","author":"M\u00fcller","year":"2021","journal-title":"Pharmacology"},{"key":"10.1016\/j.jbior.2021.100840_bib27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.disamonth.2013.08.001","article-title":"Pancreatic cancer: a comprehensive review and update","volume":"59","author":"Muniraj","year":"2013","journal-title":"Disease-a-Month: DM."},{"key":"10.1016\/j.jbior.2021.100840_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2016.40","article-title":"Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death","volume":"5","author":"Nakamura","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jbior.2021.100840_bib29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.21037\/atm.2019.10.91","article-title":"Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment","volume":"7","author":"Pu","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jbior.2021.100840_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jbior.2021.100840_bib31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 Tumor suppressor gene: important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Canc."},{"key":"10.1016\/j.jbior.2021.100840_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cancers10010016","article-title":"Locally advanced pancreatic cancer: a review of local ablative therapies","volume":"10","author":"Ruarus","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.jbior.2021.100840_bib33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2174\/138161211795222603","article-title":"Pharmacologic activation of p53 by small-molecule MDM2 antagonists","volume":"17","author":"Shen","year":"2011","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.jbior.2021.100840_bib34","first-page":"11","article-title":"Cancer statistics","volume":"63","author":"Siegel","year":"2013","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.jbior.2021.100840_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jbior.2021.100840_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.mrfmmm.2012.04.005","article-title":"Berberine, a genotoxic alkaloid, induces ATM-Chk1 mediated G2 arrest in prostate cancer cells","volume":"734","author":"Wang","year":"2012","journal-title":"Mutat. Res."},{"issue":"9","key":"10.1016\/j.jbior.2021.100840_bib37","article-title":"KRAS: the critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harbor Pre. Med."},{"key":"10.1016\/j.jbior.2021.100840_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-017-0551-7","article-title":"Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions","volume":"11","author":"Zhang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jbior.2021.100840_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergencyto.2004.09.008","article-title":"AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells","volume":"159","author":"Zhu","year":"2005","journal-title":"Cancer Genet. Cytogenet."}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492621000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492621000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:27:17Z","timestamp":1761949637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492621000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":39,"alternative-id":["S2212492621000567"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2021.100840","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2021.100840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100840"}}